Abstract-The mode of action of nefopam, a novel analgesic, on the splanchnic afferent pathway was investigated using electrophysiological methods. Nefopam (2.5 and 5.0 mg/kg, i.v.) caused arousal patterns in spontaneous rabbit EEG. In intact cats, nefopam (1.0, 2.5 and 5.0 mg/kg, i.v.) suppressed the evoked potentials recorded from the posterior sigmoid gyrus of the cortex, N. ventralis posterolateralis and N. centralis medialis of the thalamus and the ventrolateral funiculus of the spinal cord following splanchnic nerve stimulation without inhibiting potentials in the thalamo cortical pathways. These depressant effects were not antagonized by a narcotic antagonist, levallorphan (0.5 mg/kg, i.v.). The inhibitory effect of nefopam on the spinal potential evoked by splanchnic nerve stimulation was not observed in spinal cats (C1-C2 transection) and pentobarbital anesthetized cats. These results suggest that nefopam may inhibit the splanchnic afferent pathways in the spinal cord by reinforcing descending inhibitory systems originating in the supra-spinal structure, in a manner which differs from that seen with morphine.
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Nefopam hydrochloride (5-methyl -1 phenyl-1,3,4,6-tetra hydro-5H-2,5-benz [f] oxazocine hydrochloride), the structure of which is in Fig. 1 , is a novel heterocycle unrelated chemically to other analgesics.
According to Conway (2) . However, the mode of action of this compound remains unknown.
The present paper describes studies on the mode of action of nefopam using electro physiological techniques and the findings were compared with the data on morphine.
MATERIALS AND METHODS

I) Electroencephalographic studies
Three male white rabbits weighing 2.7 to 3.4 kg were used. The implantation of EEG electrodes was performed under pentobarbital anesthesia (30 mg/kg, i.v.). The electrodes were placed in the sensorimotor area of the cortex (SMC), hippocampus (HPC) (P:3, L:4, H:5) and amygdala (AMY) (A:2, L:7, H:-5), according to a stereotaxic atlas of Sawyer et al. (3) . The electrodes used were the bipolar silver ball electrodes (diameter of 1 .0 mm) for recording the cortical EEG and the bipolar concentric electrodes made from insulated stainless steel pipe except the tip (outside diameter of 0.5 mm, distance of 1 .0 mm between two electrode tip) for recording the subcortical EEG. The electrodes were connected to the miniature socket, which was fixed with dental cement to the skull. The experiments were carried out later than 3 weeks after implantation. II) Evoked potential studies Forty adult cats of both sexes weighing 2.2 to 4.8 kg were used. Xylocaine jelly was frequently applied to the tracheal cannula, ear canals, pressure points and the entire surgical areas throughout the entire experiment. Animals underwent the surgery after anesthetization with ether and were then immobilized with gallamine triethiodide, artificially ventilated and placed in a stereo taxic apparatus (Todai Noken Type). The brain and the spinal cord were exposed at appropriate locations. In some experiments, spinal cats (transected at the C1-C2 level) and pentobarbital-anesthetized cats (30 mg/ kg, i.p.) were used. The bipolar concentric electrodes for the subcortical stimulation and recording were inserted stereotaxically according to a stereotaxic atlas of Jasper and Ajmone-Marsan (4). 1) Effects on afferent pathway of the splanchnic nerve: The left splanchnic nerve was exposed and ligated at its peripheral end. The central part of the nerve end was placed on the bipolar stimulating electrodes (platinum wires) and stimulated with rectangular pulses (0.1 Hz, 1 msec, supra maximal voltage). The recording portions were right posterior sigmoid gyrus (PSG) of the cortex, right N. ventralis posterolateralis (VPL) of the thalamus (A: 9, L: 7, H: 2), right N. centralis medialis (CM) of the thalamus (A: 7, L: 3, H: 1) and right ventrolateral funiculus (VLF) of the spinal cord at the level of T3-T4. A silver ball electrode for recording the cortical evoked potentials, a stainless steel pipe insulated by enamel except for the tip (diameter of 0.5 mm) for the subcortical evoked potentials and a tungsten wire insulated except for the tip (tip diameter of 0.1 mm) for the spinal evoked potentials were used.
2) Effects on thalamo-cortical pathways: The evoked potentials were recorded from PSG of the cortex following electrical stimulation (0.3 Hz, 0.2-0.5 msec, supra maximal voltage) of CM or VPL of the thalamus. Bipolar concentric electrodes for stimulation and a monopolar silver ball electrode for records were used.
3) Effects on direct cortical response: Direct cortical response was recorded from the surface portion close to the stimulating electrode (within 5 mm) in PSG of the cortex following its electrical stimulation (0.1 Hz, 0.1 msec, supramaximal voltage). The electrodes made from platinum wires insulated by enamel except the tip were used for stimulation and recording. 
RESULTS
I) Electroencephalogical studies
In rabbits, intravenous administration of nefopam (2.5 and 5.0 mg/kg, N=3, respec tively) caused no detectable changes in the gross behavior except for tachypnea, while in cats, mydriasis, salivation, tachypnea and vomiting were frequent. The spontaneous EEG exhibited a slight alert pattern consisting of low voltage-fast waves in the sensorimotor cortex and amygdala and regular theta waves in the hippocampus in rabbits. These changes appeared quickly and lasted for about 1 hr. Further increase up to 5 mg/kg (N=3) did not enhance the EEG changes. II) Effects of afferent pathways of the splanchnic nerve 1) Evoked potentials recorded from the cerebral cortex:
The evoked potentials recorded from the posterior sigmoid gyrus of the cortex following splanchnic nerve stimu lation were composed of a first biphasic negative-positive wave with a latency of 18-30 msec succeeded by a negative wave. Intravenous administration of nefopam sup pressed the first negative-positive wave. Mean maximum decreases in amplitude at doses of 1.0 (N=5), 2.5 (N=5) and 5.0 mg/ kg (N=5) were 47%, 46% and 56%, respec tively. These suppressive effects lasted for 15 min, 90 min and more than 90 min, respectively (Fig. 2, Table 1) . Morphine (5 mg/kg, i.v., N=5) also suppressed a first negative-positive wave by 58% (Table 1) and the effect lasted for over 60 min.
2) Evoked potentials recorded from VPL: The evoked potentials recorded from VPL of the thalamus following splanchnic nerve stimulation were composed of a biphasic negative-positive wave with a latency of 13-18 msec succeeded by a negative wave. Intravenous administration of 2.5 (N=5) and 5.0 mg/kg (N=7) of nefopam suppressed markedly the first negative-positive wave (37% and 60%, respectively). These effects lasted for more than 60 min (Fig. 2) . Morphine (5.0 mg/kg, i.v., N=3) suppressed more markedly the first negative-positive wave (84%) ( Table 1 ) and the effect lasted for over 60 min. 3) Evoked potentials recorded from CM: The evoked potentials recorded from CM of the thalamus following splanchnic nerve stimulation were composed of a small early positive-negative wave followed by a large late negative wave with a latency of about 95 msec. Intravenous administration of 1.0 (N=3) and 2.5 mg/kg (N=4) of nefopam slightly depressed (20% and 28%, respec tively) a large late negative wave and a more marked suppression (63%) was observed at a dose of 5.0 mg/kg (N=7). These depressant effects lasted for 15 min, 30 min and more than 60 min, respectively (Fig. 2) . Intra venous administration of morphine (5.0 mg/kg, N=2) caused a marked suppression (about 100%) of a large late negative wave lasting for more than 60 min (Table 1) . In intact cats, the evoked potentials were suppressed by intravenous administration of nefopam. Mean maximum decreases at doses of 1.0 (N=4), 2.5 (N=4) and 5.0 mg/ kg (N=6) were 35%, 38% and 64%, re spectively (Table 1) . These effects lasted for more than 30-60 min (Fig. 3) . These sup pressive effects of nefopam on the splanchnic spinal afferent pathway were never seen in spinal cats and pentobarbital-anesthetized cats (Fig. 3, Table 2 ). Intravenous adminis tration of 5.0 mg/kg (N=5) of morphine suppressed the evoked potentials (56%) for more than 60 min in intact cats, but not in spinal cats (Table 2) .
5) Effects of levallorphan on the depressive effects of nefopam and morphine on various evoked potentials: In the evoked potentials recorded from PSG of the cortex, CM and VPL of the thalamus and VLF of the spinal cord following splanchnic nerve stimulation, the depressant effects of morphine (5.0 mg/ kg, i.v., N=5), but not of nefopam (5.0 mg/ kg i.v., N=4), were antagonized by intra venous administration of 0.5 mg/kg of levallorphan (Table 1 ). 6) Effects on the evoked potentials recorded from the cerebral cortex by VPL stimulation: The evoked potentials recorded from the posterior sigmoid gyrus of the cortex by stimulation of VPL of the thalamus were composed of an initial triphasic wave (positive-negative-positive) with a latency of a few msec succeeded by a late positive wave with a latency of about 1 5 msec.
Intravenous administration of 2.5 (N=5) and 5.0 mg/kg (N=7) of nefopam slightly enhanced the amplitude of both initial triphasic and late positive waves (Fig. 4) . Intravenous administration of 5.0 mg/kg (N=2) of morphine tended to enhance the late positive wave. 7) Effects on the evoked potentials recorded from the cerebral cortex by CM stimulation: The evoked potentials recorded from the posterior sigmoid gyrus of the cortex by stimulation of CM of the thalamus were composed of an early small biphasic wave (positive-negative) followed by a late large biphasic one (negative-positive).
Intravenous administration of 2.5 (N=4) and 5.0 mg/kg (N=5) of nefopam had no significant effect on either potential (Fig. 4) . Intravenous administration of 5.0 mg/kg (N=2) of morphine slightly suppressed these evoked potentials. 8) Effects on the direct cortical response: The evoked potentials recorded from the surface portion close to the stimulating electrodes (within 5 mm) following electrical stimulation of the cerebral cortex were composed of two negative components, early negative wave evoked immediately after stimulation succeeded by slow negative wave with a latency of 18-25 msec and a duration of 100-175 msec.
Intravenous administration of 2.5 (N=3) and 5.0 mg/kg (N=3) of nefopam slightly enhanced the amplitude of the slow negative component (21-39%) without any consistent effect on the fast negative wave (Fig. 5) . Intravenous administration of 5.0 mg/kg (N=3) of morphine slightly suppressed both components (12-23%).
DISCUSSION
Nefopam induced arousal patterns in the spontaneous EEG of the rabbit. These changes in EEG patterns differed from those caused by morphine which produced drowsy patterns in rabbits but not in cats. These results suggest that nefopam has excitatory actions on the central nervous system.
In intact cats, both nefopam and morphine suppressed the evoked potentials recorded from the cerebral cortex (PSG), thalamus (CM, VPL) and spinal cord (VLF) following splanchnic nerve stimulation. The suppressive effect of nefopam (5 mg/kg, i.v.) on the evoked potentials recorded from PSG and VLF was comparable to that of morphine (5 mg/kg, i.v.). However, the observations that the evoked potentials recorded from PSG following stimulation of VPL or CM of the thalamus were either enhanced or not influenced by nefopam administration and that the direct cortical response was enhanced suggest that nefopam may have an inhibitory effect on the spinal sensory transmission.
The depression of the spinal evoked potential was not observed in spinal cats (C1 C2 transection) even in a relatively large dose of nefopam (5 mg/kg, i.v.). This finding indicates that the inhibitory effect of nefopam, at the doses used, is not mediated by the direct action on the spinal cord, but rather through its facilitatory action on the descending inhibitory mechanism, originating in the supra-spinal structure.
Satoh and Takagi (5) suggested that there may be, in cats, at least two descending sensory-regulating mechanisms on the splanchnic afferent pathways in the ventrol ateral funiculus of the spinal cord, one susceptible to anesthetics (6) and the other resistant to them. Morphine depressed the spinal potential evoked by splanchnic nerve stimulation, even under pentobarbital anesthesia (5, 7), whereas nefopam did not suppress it under the same conditions. Therefore, nefopam may inhibit splanchnic afferent pathways in the spinal cord by reinforcing descending inhibitory systems in the supra-spinal structure, in a manner which differs from that seen with morphine.
